Kura Total Stockholder Equity from 2010 to 2024
| KURA Stock | USD 17.56 0.12 0.68% |
Total Stockholder Equity | First Reported 2008-03-31 | Previous Quarter 466.1 M | Current Value 423.8 M | Quarterly Volatility 246.9 M |
Check Kura Oncology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Kura Oncology's main balance sheet or income statement drivers, such as Other Operating Expenses of 174.1 M, Total Operating Expenses of 174.1 M or Interest Expense of 1.6 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 2.78. Kura financial statements analysis is a perfect complement when working with Kura Oncology Valuation or Volatility modules.
Kura | Total Stockholder Equity |
Latest Kura Oncology's Total Stockholder Equity Growth Pattern
Below is the plot of the Total Stockholder Equity of Kura Oncology over the last few years. It is the total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders. Kura Oncology's Total Stockholder Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Kura Oncology's overall financial position and show how it may be relating to other accounts over time.
| Total Stockholder Equity | 10 Years Trend |
|
Total Stockholder Equity |
| Timeline |
Kura Total Stockholder Equity Regression Statistics
| Arithmetic Mean | (42,490,486) | |
| Coefficient Of Variation | (626.27) | |
| Mean Deviation | 193,925,276 | |
| Median | (95,346) | |
| Standard Deviation | 266,104,476 | |
| Sample Variance | 70811.6T | |
| Range | 985.9M | |
| R-Value | (0.06) | |
| Mean Square Error | 76003T | |
| R-Squared | 0 | |
| Significance | 0.84 | |
| Slope | (3,445,452) | |
| Total Sum of Squares | 991362.3T |
Kura Total Stockholder Equity History
About Kura Oncology Financial Statements
Kura Oncology stakeholders use historical fundamental indicators, such as Kura Oncology's Total Stockholder Equity, to determine how well the company is positioned to perform in the future. Although Kura Oncology investors may analyze each financial statement separately, they are all interrelated. For example, changes in Kura Oncology's assets and liabilities are reflected in the revenues and expenses on Kura Oncology's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Kura Oncology. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Total Stockholder Equity | 397.3 M | 417.1 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Kura Oncology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Kura Oncology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Kura Oncology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Kura Oncology Stock:Check out the analysis of Kura Oncology Correlation against competitors. For information on how to trade Kura Stock refer to our How to Trade Kura Stock guide.You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kura Oncology. If investors know Kura will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kura Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.35) | Return On Assets (0.29) | Return On Equity (0.46) |
The market value of Kura Oncology is measured differently than its book value, which is the value of Kura that is recorded on the company's balance sheet. Investors also form their own opinion of Kura Oncology's value that differs from its market value or its book value, called intrinsic value, which is Kura Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kura Oncology's market value can be influenced by many factors that don't directly affect Kura Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kura Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Kura Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kura Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.